title: A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
abstract: A 47-year-old female patient with Behçet's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behçet's disease.
authors: Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
authors: Toru
authors: T
authors: Hirano
authors: Nobuyuki
authors: N
authors: Ohguro
authors: Satoshi
authors: S
authors: Hohki
authors: Keisuke
authors: K
authors: Hagihara
authors: Yoshihito
authors: Y
authors: Shima
authors: Masashi
authors: M
authors: Narazaki
authors: Atsushi
authors: A
authors: Ogata
authors: Kazuyuki
authors: K
authors: Yoshizaki
authors: Atsushi
authors: A
authors: Kumanogoh
authors: Tadamitsu
authors: T
authors: Kishimoto
authors: Toshio
authors: T
authors: Tanaka
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000473:pathology; D003078:Colchicine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069285:Infliximab; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D019947:Receptors, Interleukin-6 / Q000276:immunology*; D012074:Remission Induction; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D019947:Receptors, Interleukin-6; D016572:Cyclosporine; D011239:Prednisolone; D000069285:Infliximab; C502936:tocilizumab; D003078:Colchicine